Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge

Vaccine

Volumn 28, Issue 49, 2010, Pages 7764-7773

  Edlich, Birgit ^a,b   Hogdal, Leah J ^b   Rehermann, Barbara ^b   Behrens, Sven Erik ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cross priming; Her2; RNA replicon

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; VIRUS RNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNE RESPONSE; IN VITRO GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA REPLICATION; TUMOR IMMUNITY; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CROSS-PRIMING; DENDRITIC CELLS; IMMUNOTHERAPY; INTERLEUKIN-12; MICE; RATS; RECEPTOR, ERBB-2; REPLICON; RNA; TRANSFECTION;

EID: 78349308273     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.054     Document Type: Article

References (52)

1. Boon T., Coulie P.G., Van den Eynde B.J., van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208.
2. Lollini P.L., Cavallo F., Nanni P., Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006, 6(3):204-216.
3. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002, 20:621-667.
4. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2(1):52-58.
5. Tuyaerts S., Aerts J.L., Corthals J., Neyns B., Heirman C., Breckpot K., et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007, 56(10):1513-1537.
6. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7(10):790-802.
7. Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008, 8(5):351-360.
8. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004, 199:9-26.
9. Albert M.L., Pearce S.F., Francisco L.M., Sauter B., Roy P., Silverstein R.L., et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998, 188(7):1359-1368.
10. Burgdorf S., Scholz C., Kautz A., Tampe R., Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 2008, 9(5):558-566.
11. Cho J.H., Youn J.W., Sung Y.C. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 2001, 167(10):5549-5557.
12. Gasteiger G., Kastenmuller W., Ljapoci R., Sutter G., Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 2007, 81(21):11925-11936.
13. Racanelli V., Behrens S.E., Aliberti J., Rehermann B. Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. Immunity 2004, 20(1):47-58.
14. Behrens S.E., Grassmann C.W., Thiel H.J., Meyers G., Tautz N. Characterization of an autonomous subgenomic pestivirus RNA replicon. J Virol 1998, 72(3):2364-2372.
15. Tautz N., Harada T., Kaiser A., Rinck G., Behrens S., Thiel H.J. Establishment and characterization of cytopathogenic and noncytopathogenic pestivirus replicons. J Virol 1999, 73(11):9422-9432.
16. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9(7):463-475.
17. Shen Z., Reznikoff G., Dranoff G., Rock K.L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997, 158(6):2723-2730.
18. Reilly R.T., Gottlieb M.B., Ercolini A.M., Machiels J.P., Kane C.E., Okoye F.I., et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000, 60(13):3569-3576.
19. Yu H., Isken O., Grassmann C.W., Behrens S.E. A stem-loop motif formed by the immediate 5' terminus of the bovine viral diarrhea virus genome modulates translation as well as replication of the viral RNA. J Virol 2000, 74(13):5825-5835.
20. Corapi W.V., Donis R.O., Dubovi E.J. Characterization of a panel of monoclonal antibodies and their use in the study of the antigenic diversity of bovine viral diarrhea virus. Am J Vet Res 1990, 51(9):1388-1394.
21. Wiskerchen M., Belzer S.K., Collett M.S. Pestivirus gene expression: the first protein product of the bovine viral diarrhea virus large open reading frame, p20, possesses proteolytic activity. J Virol 1991, 65(8):4508-4514.
22. Carreno V., Zeuzem S., Hopf U., Marcellin P., Cooksley W.G., Fevery J., et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 2000, 32(2):317-324.
23. Schadendorf D., Ugurel S., Schuler-Thurner B., Nestle F.O., Enk A., Brocker E.B., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006, 17(4):563-570.
24. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007, 117(5):1195-1203.
25. Ercolini A.M., Machiels J.P., Chen Y.C., Slansky J.E., Giedlen M., Reilly R.T., et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003, 170(8):4273-4280.
26. Tegerstedt K., Franzen A., Ramqvist T., Dalianis T. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunol Immunother 2007, 56(9):1335-1344.
27. Park J.M., Terabe M., Steel J.C., Forni G., Sakai Y., Morris J.C., et al. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res 2008, 68(6):1979-1987.
28. Jirmo A.C., Nagel C.H., Bohnen C., Sodeik B., Behrens G.M. Contribution of direct and cross-presentation to CTL immunity against herpes simplex virus 1. J Immunol 2009, 182(1):283-292.
29. Winau F., Weber S., Sad S., de Diego J., Hoops S.L., Breiden B., et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 2006, 24(1):105-117.
30. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425(6957):516-521.
31. Ying H., Zaks T.Z., Wang R.F., Irvine K.R., Kammula U.S., Marincola F.M., et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med 1999, 5(7):823-827.
32. Anraku I., Harvey T.J., Linedale R., Gardner J., Harrich D., Suhrbier A., et al. Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol 2002, 76(8):3791-3799.
33. Cassetti M.C., McElhiney S.P., Shahabi V., Pullen J.K., Le Poole I.C., Eiben G.L., et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004, 22(3-4):520-527.
34. Cheng W.F., Lee C.N., Su Y.N., Chai C.Y., Chang M.C., Polo J.M., et al. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. Cancer Gene Ther 2006, 13(9):873-885.
35. Diebold S.S. Activation of dendritic cells by toll-like receptors and C-type lectins. Handb Exp Pharmacol 2009, (188):3-30.
36. Werling D., Ruryk A., Heaney J., Moeller E., Brownlie J. Ability to differentiate between cp and ncp BVDV by microarrays: towards an application in clinical veterinary medicine?. Vet Immunol Immunopathol 2005, 108(1-2):157-164.
37. Watts C., West M.A., Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr Opin Immunol 2010, 22(1):124-130.
38. Le Bon A., Tough D.F. Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev 2008, 19(1):33-40.
39. Chen Y., Emtage P., Zhu Q., Foley R., Muller W., Hitt M., et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 2001, 8(4):316-323.
40. Mukai K., Yasutomi Y., Watanabe M., Kenjo A., Aota T., Wang L., et al. HER2 peptide-specific CD8(+) T cells are proportionally detectable long after multiple DNA vaccinations. Gene Ther 2002, 9(13):879-888.
41. Pilon S.A., Piechocki M.P., Wei W.Z. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 2001, 167(6):3201-3206.
42. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77(7):1303-1310.
43. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009, 21(2):233-240.
44. Bevan M.J. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004, 4(8):595-602.
45. Schattner E.J., Mascarenhas J., Bishop J., Yoo D.H., Chadburn A., Crow M.K., et al. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Blood 1996, 88(4):1375-1382.
46. Nakanishi Y., Lu B., Gerard C., Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009, 462(7272):510-513.
47. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007, 13(16):4677-4685.
48. Lindencrona J.A., Preiss S., Kammertoens T., Schuler T., Piechocki M., Wei W.Z., et al. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004, 109(2):259-264.
49. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51.
50. Lindenbach B.D., Thiel H.J., Rice C.M. Flaviviridae: the viruses and their replication. 3 Fields BN Virology 2007, 1101-1152. Lippincott Williams & Wilkins. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
51. Singh R., Paterson Y. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Cancer Res 2006, 66(15):7748-7757.
52. Singh R., Paterson Y. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother 2007, 56(6):927-938.